Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 785

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 785
---
 | ​              
 ​              |                       ​ 
 As of December 31, 2022 | ​ | ​          |      ​ |
|:----------------------|:--|:---------------|------------------------:|:--|:-----------|-------:|:--|:---------------|------------------------:|:--|:-----------|-------:|
| Contractual maturity  |   | Amortized Cost |                         |   | Fair Value |        |   | Amortized Cost |                         |   | Fair Value |        |
| Less than one year    | ​ | $              |                  49,243 | ​ | $          | 48,983 | ​ | $              |                  82,678 | ​ | $          | 81,658 |
| One year to two years | ​ |                |                       — | ​ |            |      — | ​ |                |                  12,002 | ​ |            | 11,350 |
| Total                 | ​ | $              |                  49,243 | ​ | $          | 48,983 | ​ | $              |                  94,680 | ​ | $          | 93,008 |

All available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Other income, net includes interest and dividends, accretion/amortization of discounts/premiums, realized gains and losses on sales of securities and credit loss expense due to declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method.

There werenosales of available-for-sale marketable securities during the years ended December 31, 2023 and 2022. During the year ended December 31, 2021, the Company sold certain of its available-for-sale debt securities with a total fair value of$ 10,029, which resulted in realized gains of$ 39.

As of December 31, 2023 and 2022, accrued interest receivables on our available-for-sale debt securities were$ 139and$ 489, respectively.

F-55

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data)

4. Accumulated Other Comprehensive (Loss) Income

The following table summarizes the changes in accumulated other comprehensive (loss) income, net of